

NCT ID	NCT05198934
Title	Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)
Phase	Phase 3
Date Added	2022-01-20
Location	Alabama, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia France Germany Greece Italy Japan Korea, Republic of Mexico Spain Taiwan United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT05194735
Title	Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Phase	Phase 1
Date Added	2022-01-18
Location	Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Aldesleukin (IL-2), Neoantigen specific TCR-T cell drug product
Tags	MSS/ MMRp

NCT ID	NCT05167409
Title	A Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2021-12-22
Location	Arizona, United States Colorado, United States New Jersey, United States Virginia, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	ALX148, cetuximab, Evorpacept (ALX148), Pembrolizumab, Erbitux, Keytruda

Tags	MSS/ MMRp
NCT ID	NCT05141721
Title	A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2021-12-02
Location	Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin
Tags	MSS/ MMRp
NCT ID	NCT05141474
Title	Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Phase	Early Phase 1
Date Added	2021-12-02
Location	Spain
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05107674
Title	A Study of NX-1607 in Adults With Advanced Malignancies
Phase	Phase 1
Date Added	2021-11-04

Location	California, United States Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	NX-1607
Tags	MSS/ MMRp
NCT ID	NCT05019534
Title	Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2021-08-25
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Camrelizumab, Cetuximab Injection [Erbix], Vemurafenib Oral Tablet [Zelboraf]
Tags	MSS/ MMRp
NCT ID	NCT04991948
Title	Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2021-08-05
Location	Florida, United States Belgium
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	CYAD-101, FOLFOX, Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04984369
Title	The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
Phase	Phase 2
Date Added	2021-07-30
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Cetuximab Injection [Erbix], HLX208
Tags	MSS/ MMRp
NCT ID	NCT04973163
Title	A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Phase	Phase 1
Date Added	2021-07-22
Location	Texas, United States Belgium Spain United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	BI 1701963, BI 1823911, Midazolam
Tags	MSS/ MMRp